Memantine and Comprehensive, Individualized, Patient Centered Management of Alzheimer's Disease: Health Outcome
Memantine and Comprehensive, Individualized, Patient Centered Management of Alzheimer's Disease: A Randomized Controlled Trial: Further Study, Health Outcome
This study is a retrospective review of the data collected in a previously completed randomized, controlled trial (RCT) entitled "Memantine and Comprehensive, Individualized, Patient Centered Management of Alzheimer's Disease: A Randomized Controlled Trial" (NCT00120874). As part of the previously completed RCT, participants with Alzheimer's Disease (AD) were randomly placed into one of two groups: memantine, or memantine plus an individualized management program consisting of home visits, educational sessions for caregivers, and a caregiver support group. Participants received the study intervention for 28 weeks; study follow-up lasted for 52 weeks.
The collected data from the existing study books from the 28 week treatment portion of the RCT will be carefully examined with respect to each of the research questions for the present retrospective study.
Visão geral do estudo
Status
Condições
Tipo de estudo
Inscrição (Real)
Contactos e Locais
Locais de estudo
-
-
New York
-
New York, New York, Estados Unidos, 10016
- New York University School of Medicine
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
Descrição
Inclusion Criteria:
- Previously participated in the "Memantine and Comprehensive, Individualized, Patient Centered Management of Alzheimer's Disease: A Randomized Controlled Trial" study.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Modelos de observação: Controle de caso
- Perspectivas de Tempo: Retrospectivo
Coortes e Intervenções
Grupo / Coorte |
|---|
|
Memantine Alone
10 subjects who previously participated in the "Memantine and Comprehensive, Individualized, Patient Centered Management of Alzheimer's Disease: A Randomized Controlled Trial" study will be enrolled in this cohort.
These subjects received memantine for a period of 28 weeks.
|
|
Memantine plus Individualized Management of AD
10 subjects who previously participated in the "Memantine and Comprehensive, Individualized, Patient Centered Management of Alzheimer's Disease: A Randomized Controlled Trial" study will be enrolled in this cohort.
These subjects received memantine plus individualized management of AD for a period of 28 weeks.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Prazo |
|---|---|
|
Total number of prescription medications taken throughout the study
Prazo: 28 weeks
|
28 weeks
|
|
Total number of hospitalizations
Prazo: 28 weeks
|
28 weeks
|
|
The total number of new medical conditions
Prazo: 28 weeks
|
28 weeks
|
|
Total number of days of hospice care
Prazo: 28 weeks
|
28 weeks
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Total number of psychotropic medications used
Prazo: 28 weeks
|
28 weeks
|
|
|
Total number of increases in psychotropic medications
Prazo: 28 weeks
|
28 weeks
|
|
|
Total number of decreases in psychotropic medications
Prazo: 28 weeks
|
28 weeks
|
|
|
Total number of cardiac medications taken during the study
Prazo: 28 weeks
|
28 weeks
|
|
|
Total number arthritic and anti-inflammatory medications taken during the study
Prazo: 28 weeks
|
28 weeks
|
|
|
Total number of analgesic medications taken during the study
Prazo: 28 weeks
|
28 weeks
|
|
|
Total number of days hospitalized during the study
Prazo: 28 weeks
|
28 weeks
|
|
|
Reasons for hospitalizations and hospital diagnoses during the study
Prazo: 28 weeks
|
This endpoint will be examined qualitatively; no statistical analysis will be performed but the data will be compiled and reported for illustrative purposes
|
28 weeks
|
|
Total number of tests and procedures performed during the hospitalizations
Prazo: 28 weeks
|
28 weeks
|
|
|
Changes in Functional Assessment Staging Disability Score (FAST-DS) at subsequent study visits post hospitalization
Prazo: 28 weeks
|
The FAST-DS assesses the magnitude of progressive functional deterioration by identifying characteristic progressive disabilities in participants with AD. Scores range from 1.0 (normal) to 7f (severe loss of ability, not even able to hold up head independently). Scores are made up of stages (1 through 7) and substages (from a to e for stage 6; from a to f for stage 7). The following scoring for substages is applied: 6a=6.0, 6b=6.2, 6c=6.4, 6d=6.6, 6e=6.8, 7a=7.0, 7b=7.2, 7c=7.4, 7d=7.6, 7e=7.8, 7f=8.0. Additionally, non-consecutive deficits are noted and scored as follows: full stage non-consecutive deficit=1.0, non-consecutive substage deficit=0.2. The overall FAST-DS score = (FAST Stage Score) + (Each Non-Consecutive FAST disability scored as described) |
28 weeks
|
|
Time to death
Prazo: 28 weeks
|
28 weeks
|
|
|
Cause of death
Prazo: 28 weeks
|
This endpoint will be examined qualitatively; no statistical analysis will be performed but the data will be compiled and reported for illustrative purposes
|
28 weeks
|
|
Caregiver training and support in relation to mortality
Prazo: 28 weeks
|
This endpoint will be examined qualitatively; no statistical analysis will be performed but the data will be compiled and reported for illustrative purposes
|
28 weeks
|
|
Differences in rate of fecal incontinence
Prazo: 28 weeks
|
28 weeks
|
|
|
Differences in rate of urinary incontinence
Prazo: 28 weeks
|
28 weeks
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Barry Reisberg, MD, NYU Langone Health
Publicações e links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 12444
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .